Market News & Trends
Isis Pharmaceuticals, Inc. to Receive $7.5 Million From Alnylam
Isis Pharmaceuticals, Inc. recently announced it will receive $7.5 million from Alnylam Pharmaceuticals, Inc. from the recently announced alliance between Genzyme and Alnylam. In addition,…
NantBioScience Announces Strategic Collaboration With Celgene
NantBioScience recently announced a strategic collaboration with Celgene to advance bold research programs to benefit cancer patients in need of new therapeutic solutions. As part…
CytomX Therapeutics & ImmunoGen Announce Strategic Collaboration
CytomX Therapeutics and ImmunoGen, Inc. recently announced a multi-year, strategic collaboration to develop Probody-drug conjugate (PDC) therapies for the treatment of cancer. Probodies are a…
Aptalis to be Acquired by Forest Laboratories for $2.9 Billion
Aptalis recently announced that it has signed a definitive agreement to be acquired by Forest Laboratories, Inc. Forest has agreed to acquire Aptalis from TPG,…
Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market
The need for effective and patient-friendly treatment of retinal diseases to avoid visual impairment is driving the retinal therapeutics market in the US. Vascular endothelial…
Marina Biotech Strengthens IP Estate for SMARTICLES Nucleic Acid Delivery Technology
Marina Biotech, Inc. recently announced the grant and issuance of patents relating to the company's proprietary nucleic-acid delivery technology, SMARTICLES. The US Patent and Trademark…
Santaris A/S Announces Worldwide Discovery Alliance for RNA-Targeted Medicines With Roche
Santaris Pharma A/S recently announced it has signed a worldwide strategic alliance with Roche to discover and develop novel RNA targeted medicines using Santaris Pharma's…
AAIPharma Announces Completion of Parenteral Manufacturing Facility Expansion
AAIPharma Services Corp recently announced it has completed a multi-million dollar expansion of its cGMP parenteral manufacturing facility in Charleston, SC. The expansion consisted of…
New Report on Global Markets for Advanced Drug Delivery Systems
According to a new technical market research report, Global Markets and Technologies for Advanced Drug Delivery Systems, from BCC Research (http://www.bccresearch.com), the global market for…
DNAnexus, Inc. Secures $15 Million in Financing, Led by Google Ventures
DNAnexus recently announced it has closed a $15-million Series C funding led by Claremont Creek Ventures, Google Ventures, TPG Biotech, and First Round Capital. The…
Scioderm Initiates Phase IIB Study
Scioderm, Inc. recently announced the initiation of a Phase IIB study designed to evaluate the efficacy and safety of SD-101, a novel topical therapy, for…
FDA Endorses, Pushes for Abuse-Resistant Opioid Formulations: Transition to Disrupt Pain Market
The opioid market is dominated by non-tamper-resistant formulations (TRFs), but the FDA’s promotion of TRF therapies could well result in the departure of non-TRF therapies…
Merck Plans Radical Overhaul of R&D Unit
Merck & Co. Inc. is working on a plan to radically reshape its once-storied R&D unit that would create international innovation hubs tapping into drug…
Encap Announces Collaboration With Lipocine
Encap Drug Delivery, part of Capsugel’s Dosage Form Solutions (DFS) business unit, recently announced a collaboration with Lipocine Inc. to manufacture Phase III clinical trial…
Unilife Signs Agreement With Global Pharma Company Seeking to Use Ocu-Ject
Unilife Signs Agreement With Global Pharma Company Seeking to Use Ocu-Ject Unilife Corporation recently announced the signing of an agreement with a global pharmaceutical…
Lightlake Therapeutics Joint Clinical Trial With NIDA Shows Nasal Delivery of Naloxone for Opioid Overdose to be Promising
Lightlake Therapeutics Inc. recently announced the initial findings of its clinical trial with the National Institute on Drug Abuse (NIDA), part of the National Institutes…
Adocia Signs Exclusive Nanotechnology License
Adocia recently announced the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science…
Monoclonal Antibodies Market for Colorectal Cancer to Witness Moderate Growth, as Late-Stage Pipeline Remains Weak
The market value for monoclonal antibodies (mAbs) in colorectal cancer treatment will experience a moderate increase from $3.7 billion in 2012 to $5.2 billion by…
Antitope Enters Research Agreement with Annexon to Generate Novel Therapeutic Antibodies
Antitope Ltd recently announced it has entered a research agreement with Annexon to generate novel antibody therapeutics for the treatment of neurodegenerative diseases. Under the…
Peptineo Inks Exclusive Option for Drug Delivery Technologies
Peptineo recently announced the company has inked an exclusive option for a broad set of nanotechnology patents in the area of drug delivery from Lawrence…
